ACADIA Pharmaceuticals Inc.(ACAD)Earnings, Financials & Key Ratios

ACAD•NASDAQ

$21.48

$3.68B mkt cap·9.4× P/E·Price updated May 6, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryNeuroscience and Psychiatry Therapies

AboutACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.Show more

Revenue$1.07B+11.9%
EBITDA$139M-43.7%
Net Income$391M+72.7%
EPS (Diluted)2.29+68.4%
Gross Margin91.69%+0.3%
EBITDA Margin12.96%-49.7%
Operating Margin9.78%-59.4%
Net Margin36.49%+54.3%
ROE39.89%+2.6%
ROIC10.03%-77.8%
Debt/Equity0.04-40.1%

Technical→

ACAD Key Insights

ACADIA Pharmaceuticals Inc. (ACAD) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Company is almost debt free
✓Excellent 3Y average ROE of 21.4%
✓Strong 5Y sales CAGR of 19.4%

✗Weaknesses

✗Low quality earnings: Net income not backed by cash flow

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

ACAD Price & Volume

ACADIA Pharmaceuticals Inc. (ACAD) stock price & volume — 10-year historical chart

Loading chart...

ACAD Growth Metrics

ACADIA Pharmaceuticals Inc. (ACAD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years165.75%

5 Years19.39%

3 Years27.48%

TTM11.87%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM72.66%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM68.38%

Return on Capital

10 Years-32.59%

5 Years-7.59%

3 Years10.2%

Last Year10.08%

ACAD Recent Earnings

ACADIA Pharmaceuticals Inc. (ACAD) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 10/12 qtrs (83%)●Beat Revenue 5/12 qtrs (42%)

Q1 2026Latest

Feb 25, 2026

EPS

$1.60

Est $0.14

+1067.9%

Revenue

$284M

Est $293M

-3.0%

Q4 2025

Nov 5, 2025

EPS

$0.26

Est $0.14

+85.7%

Revenue

$279M

Est $293M

-4.8%

Q3 2025

Aug 6, 2025

EPS

$0.16

Est $0.14

+14.3%

Revenue

$265M

Est $262M

+1.0%

Q2 2025

May 7, 2025

EPS

$0.11

Est $0.10

+10.0%

Revenue

$244M

Est $239M

+2.2%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q1 2026Latest	Feb 25, 2026	$1.60vs $0.14+1067.9%	$284Mvs $293M-3.0%
Q4 2025	Nov 5, 2025	$0.26vs $0.14+85.7%	$279Mvs $293M-4.8%
Q3 2025	Aug 6, 2025	$0.16vs $0.14+14.3%	$265Mvs $262M+1.0%
Q2 2025	May 7, 2025	$0.11vs $0.10+10.0%	$244Mvs $239M+2.2%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
INVAInnoviva, Inc.Direct Competitor	1.91B	22.52	6.82	18.52%	118.91%	46.47%	0.23
AXSMAxsome Therapeutics, Inc.Direct Competitor	11.46B	222.63	-60.50	65.55%	-26.59%	-260.01%	2.73
INTRInter & Co, Inc.Direct Competitor	2.54B	7.84	18.70	27.12%		12.37%	1.31
PTCTPTC Therapeutics, Inc.Direct Competitor	5.52B	66.61	8.56	114.51%	39.44%
BIIBBiogen Inc.Product Competitor	28.15B	190.68	21.59	1.39%	13.92%	7.55%	0.38
ALKSAlkermes plcProduct Competitor	5.89B	35.32	24.70	-5.25%	9.78%	8.82%	0.04
SUPNSupernus Pharmaceuticals, Inc.Product Competitor	2.96B	51.45	-75.66	8.63%	-3.74%	-2.73%	0.04
JAZZJazz Pharmaceuticals plcProduct Competitor	14.34B	228.57	-39.14	4.88%	0.66%	0.71%	1.26

Compare ACAD vs Peers

ACADIA Pharmaceuticals Inc. (ACAD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs INVA

Most directly comparable listed peer for ACAD.

Scale Benchmark

vs CVS

Larger-name benchmark to compare ACAD against a more recognizable public peer.

Peer Set

Compare Top 5

vs INVA, AXSM, INTR, PTCT

ACAD Income Statement

ACADIA Pharmaceuticals Inc. (ACAD) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Sales/Revenue	124.9M	223.81M	339.08M	441.75M	484.14M	517.24M	726.44M	957.8M	1.07B
Revenue Growth %	620.68%	79.19%	51.5%	30.28%	9.6%	6.83%	40.45%	31.85%	11.87%
Cost of Goods Sold	13.06M	18.33M	19.6M	20.55M	19.14M	10.17M	45.73M	81.84M	89M
COGS % of Revenue	10.46%	8.19%	5.78%	4.65%	3.95%	1.97%	6.3%	8.54%	8.31%
Gross Profit	111.84M▲ 0%	205.48M▲ 83.7%	319.48M▲ 55.5%	421.2M▲ 31.8%	465M▲ 10.4%	507.07M▲ 9.0%	680.71M▲ 34.2%	875.96M▲ 28.7%	982.51M▲ 12.2%
Gross Margin %	89.54%	91.81%	94.22%	95.35%	96.05%	98.03%	93.7%	91.46%	91.69%
Gross Profit Growth %	765.31%	83.72%	55.48%	31.84%	10.4%	9.05%	34.24%	28.68%	12.16%
Operating Expenses	404.25M	452.92M	566.02M	707.79M	635.44M	730.66M	754.09M	645.16M	877.7M
OpEx % of Revenue	323.66%	202.37%	166.93%	160.22%	131.25%	141.26%	103.81%	67.36%	81.91%
Selling, General & Admin	255.06M	265.76M	325.64M	388.66M	396.03M	369.09M	402.47M	488.43M	548.89M
SG&A % of Revenue	204.21%	118.74%	96.04%	87.98%	81.8%	71.36%	55.4%	50.99%	51.23%
Research & Development	149.19M	187.16M	240.38M	319.13M	239.41M	361.57M	351.62M	303.25M	328.8M
R&D % of Revenue	119.45%	83.63%	70.89%	72.24%	49.45%	69.91%	48.4%	31.66%	30.69%
Other Operating Expenses	3.98M	-1.84M	0	0	0	0	0	-146.51M	0
Operating Income	-292.41M▲ 0%	-247.44M▲ 15.4%	-246.54M▲ 0.4%	-286.59M▼ 16.2%	-170.44M▲ 40.5%	-223.6M▼ 31.2%	-73.38M▲ 67.2%	230.79M▲ 414.5%	104.81M▼ 54.6%
Operating Margin %	-234.11%	-110.56%	-72.71%	-64.87%	-35.2%	-43.23%	-10.1%	24.1%	9.78%
Operating Income Growth %	-7.18%	15.38%	0.36%	-16.24%	40.53%	-31.19%	67.18%	414.52%	-54.59%
EBITDA	-289.7M	-244.44M	-243.78M	-283.65M	-167.09M	-221.57M	-67.83M	246.68M	138.9M
EBITDA Margin %	-231.94%	-109.22%	-71.9%	-64.21%	-34.51%	-42.84%	-9.34%	25.75%	12.96%
EBITDA Growth %	-6.9%	15.62%	0.27%	-16.36%	41.09%	-32.6%	69.39%	463.69%	-43.69%
D&A (Non-Cash Add-back)	2.71M	3M	2.77M	2.93M	3.34M	2.03M	5.55M	15.88M	0
EBIT	-292.41M	-247.44M	-246.54M	-286.59M	-170.44M	-223.6M	-73.38M	84.28M	138.9M
Net Interest Income	4.13M	5.35M	11.16M	6.61M	591K	6.61M	17.23M	25.46M	31.72M
Interest Income	4.13M	5.35M	11.16M	6.61M	591K	6.61M	17.23M	25.46M	31.72M
Interest Expense	0	0	0	0	0	0	0	0	0
Other Income/Expense	4.13M	3.51M	12.16M	5.61M	2.92M	10.15M	22.34M	27.28M	34.09M
Pretax Income	-288.28M▲ 0%	-243.94M▲ 15.4%	-234.38M▲ 3.9%	-280.97M▼ 19.9%	-167.52M▲ 40.4%	-213.44M▼ 27.4%	-51.04M▲ 76.1%	258.07M▲ 605.7%	138.9M▼ 46.2%
Pretax Margin %	-230.81%	-108.99%	-69.12%	-63.6%	-34.6%	-41.27%	-7.03%	26.94%	12.96%
Income Tax	1.12M	1.26M	876K	611K	351K	2.53M	10.25M	31.62M	-252.1M
Effective Tax Rate %	-0.39%	-0.51%	-0.37%	-0.22%	-0.21%	-1.19%	-20.08%	12.25%	-181.49%
Net Income	-289.4M▲ 0%	-245.19M▲ 15.3%	-235.26M▲ 4.1%	-281.58M▼ 19.7%	-167.87M▲ 40.4%	-215.97M▼ 28.7%	-61.29M▲ 71.6%	226.45M▲ 469.5%	391M▲ 72.7%
Net Margin %	-231.71%	-109.56%	-69.38%	-63.74%	-34.67%	-41.76%	-8.44%	23.64%	36.49%
Net Income Growth %	-6.64%	15.28%	4.05%	-19.69%	40.38%	-28.66%	71.62%	469.5%	72.66%
Net Income (Continuing)	-289.4M	-245.19M	-235.26M	-281.58M	-167.87M	-215.97M	-61.29M	226.45M	391M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)	-2.36▲ 0%	-1.94▲ 17.8%	-1.60▲ 17.5%	-1.79▼ 11.9%	-1.05▲ 41.3%	-1.34▼ 27.6%	-0.37▲ 72.4%	1.36▲ 467.6%	2.29▲ 68.4%
EPS Growth %	-0.85%	17.8%	17.53%	-11.88%	41.34%	-27.62%	72.39%	467.57%	68.38%
EPS (Basic)	-2.36	-1.94	-1.60	-1.79	-1.05	-1.34	-0.37	1.37	2.32
Diluted Shares Outstanding	122.6M	126.58M	147.2M	157.33M	160.49M	161.68M	163.82M	166.36M	171.36M
Basic Shares Outstanding	122.6M	126.58M	147.2M	157.33M	160.49M	161.68M	163.82M	165.72M	169.34M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

ACAD Balance Sheet

ACADIA Pharmaceuticals Inc. (ACAD) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Total Current Assets	373.48M	526.11M	760.25M	717.62M	617.82M	507.94M	616.13M	938.32M	1.06B
Cash & Short-Term Investments	341.34M	473.52M	697.43M	631.96M	520.71M	416.82M	438.87M	755.99M	819.69M
Cash Only	69.42M	134.76M	189.68M	326.03M	147.44M	114.85M	188.66M	319.59M	177.69M
Short-Term Investments	271.92M	338.76M	507.75M	305.93M	373.27M	301.98M	250.21M	436.4M	641.99M
Accounts Receivable	18.43M	27.79M	37.87M	50.28M	65.34M	63.08M	102.35M	104.69M	148.23M
Days Sales Outstanding	53.86	45.32	40.77	41.55	49.26	44.51	51.43	39.9	50.49
Inventory	5.25M	4.07M	6.34M	9.68M	7.88M	6.64M	35.82M	21.95M	34.67M
Days Inventory Outstanding	146.67	81.04	118.1	171.97	150.28	238.26	285.89	97.89	142.19
Other Current Assets	0	0	0	0	0	0	0	0	0
Total Non-Current Assets	11.03M	14.1M	22.93M	65M	82.3M	79.88M	132.83M	249.44M	502.08M
Property, Plant & Equipment	2.66M	3.31M	12.7M	56.44M	66.31M	61.59M	56.47M	50.79M	54.87M
Fixed Asset Turnover	46.92x	67.64x	26.69x	7.83x	7.30x	8.40x	12.86x	18.86x	19.53x
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	5.54M	4.06M	2.58M	1.11M	0	0	65.49M	119.78M	108.89M
Long-Term Investments	2.48M	4.83M	7.09M	7.07M	0	12.97M	5.77M	0	7.84M
Other Non-Current Assets	2.83M	6.72M	557K	378K	15.98M	5.31M	5.1M	78.87M	80.6M
Total Assets	384.51M▲ 0%	540.2M▲ 40.5%	783.18M▲ 45.0%	782.62M▼ 0.1%	700.12M▼ 10.5%	587.81M▼ 16.0%	748.96M▲ 27.4%	1.19B▲ 58.6%	1.56B▲ 31.7%
Asset Turnover	0.32x	0.41x	0.43x	0.56x	0.69x	0.88x	0.97x	0.81x	0.69x
Asset Growth %	-31.48%	40.49%	44.98%	-0.07%	-10.54%	-16.04%	27.41%	58.59%	31.69%
Total Current Liabilities	49.03M	59.56M	74.83M	105.97M	96.07M	125.63M	254.25M	394.87M	277.11M
Accounts Payable	8.79M	3.17M	7.22M	8.49M	6.88M	12.75M	17.54M	16.19M	10.9M
Days Payables Outstanding	245.55	63.06	134.51	150.85	131.12	457.63	140.02	72.21	44.72
Short-Term Debt	0	0	3.43M	5.09M	0	0	9.4M	0	11.63M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0
Other Current Liabilities	21.39M	33.52M	31.76M	52.46M	25.9M	49.51M	92.31M	36.55M	254.58M
Current Ratio	7.62x	8.83x	10.16x	6.77x	6.43x	4.04x	2.42x	2.38x	3.83x
Quick Ratio	7.51x	8.76x	10.08x	6.68x	6.35x	3.99x	2.28x	2.32x	3.71x
Cash Conversion Cycle	-45.02	63.3	24.36	62.66	68.43	-174.86	197.3	65.57	147.97
Total Non-Current Liabilities	191K	1.56M	9.22M	49.64M	63.16M	61.77M	62.95M	60.09M	59.69M
Long-Term Debt	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	6.36M	44.46M	56.13M	52.7M	47.8M	42.04M	40.55M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	191K	1.56M	2.86M	5.18M	7.03M	9.07M	15.15M	18.06M	19.14M
Total Liabilities	49.22M	61.12M	84.05M	155.61M	159.23M	187.4M	317.2M	454.96M	336.81M
Total Debt	0	0	9.79M	49.55M	64.43M	62M	57.2M	51.99M	52.19M
Net Debt	-69.42M	-134.76M	-179.88M	-276.48M	-83M	-52.85M	-131.45M	-267.59M	-125.51M
Debt / Equity	-	-	0.01x	0.08x	0.12x	0.15x	0.13x	0.07x	0.04x
Debt / EBITDA	-	-	-	-	-	-	-	0.21x	0.38x
Net Debt / EBITDA	-	-	-	-	-	-	-	-1.08x	-0.90x
Interest Coverage	-	-	-	-	-	-	-	-	-
Total Equity	335.29M▲ 0%	479.08M▲ 42.9%	699.13M▲ 45.9%	627.01M▼ 10.3%	540.89M▼ 13.7%	400.41M▼ 26.0%	431.75M▲ 7.8%	732.79M▲ 69.7%	1.23B▲ 67.5%
Equity Growth %	-35.32%	42.89%	45.93%	-10.32%	-13.73%	-25.97%	7.83%	69.72%	67.49%
Book Value per Share	2.73	3.78	4.75	3.99	3.37	2.48	2.64	4.40	7.16
Total Shareholders' Equity	335.29M	479.08M	699.13M	627.01M	540.89M	400.41M	431.75M	732.79M	1.23B
Common Stock	12K	14K	15K	16K	16K	16K	16K	16K	16K
Retained Earnings	-1.22B	-1.47B	-1.7B	-1.99B	-2.15B	-2.37B	-2.43B	-2.2B	-1.81B
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	-399K	-372K	297K	36K	-192K	-975K	24K	292K	1.45M
Minority Interest	0	0	0	0	0	0	0	0	0

ACAD Cash Flow Statement

ACADIA Pharmaceuticals Inc. (ACAD) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Cash from Operations	-217.86M	-167.47M	-151.13M	-136.17M	-125.66M	-114.03M	16.7M	157.72M	109.84M
Operating CF Margin %	-174.42%	-74.83%	-44.57%	-30.82%	-25.96%	-22.05%	2.3%	16.47%	10.25%
Operating CF Growth %	-3.54%	23.13%	9.76%	9.9%	7.72%	9.25%	114.65%	844.31%	-30.36%
Net Income	-289.4M	-245.19M	-235.26M	-281.58M	-167.87M	-215.97M	-61.29M	226.45M	391M
Depreciation & Amortization	2.71M	3M	2.77M	2.93M	3.34M	2.03M	5.55M	15.88M	11.76M
Stock-Based Compensation	75.53M	81.56M	82.27M	84.42M	63.62M	68.2M	66.42M	67.05M	0
Deferred Taxes	0	0	0	2.75M	0	0	0	0	-249.88M
Other Non-Cash Items	-287K	1.35M	-4.61M	44.28M	75K	-6.28M	-12.12M	-155.82M	46.71M
Working Capital Changes	-6.41M	-8.2M	3.71M	11.04M	-24.82M	37.99M	18.13M	4.16M	-89.76M
Change in Receivables	-11.44M	-8.75M	-9.69M	-12.47M	-16.12M	2.26M	-39.27M	-2.35M	-43.54M
Change in Inventory	-1.01M	1.93M	-1.74M	-3.32M	-4.21M	2.42M	-28.81M	-49.55M	-18.2M
Change in Payables	4.87M	-5.62M	4.05M	1.27M	-1.62M	5.87M	4.8M	-1.35M	-5.29M
Cash from Investing	92.47M	-71.49M	-165.84M	192.51M	-71.1M	73.24M	32M	-30.54M	-302.56M
Capital Expenditures	-812K	-2.15M	-1.13M	-7.59M	-1.12M	0	-40.05M	-523K	-103.53M
CapEx % of Revenue	0.65%	0.96%	0.33%	1.72%	0.23%	-	5.51%	0.05%	9.66%
Acquisitions	0	44K	164.71M	-200.1M	69.98M	0	-32.05M	0	0
Investments	-	-	-	-	-	-	-	-	-
Other Investing	93.28M	44K	-164.71M	200.1M	-69.98M	0	32.05M	146.51M	0
Cash from Financing	31.19M	306.65M	371.85M	81M	18.16M	8.2M	25.13M	6.84M	49.88M
Debt Issued (Net)	0	0	0	0	0	0	0	0	0
Equity Issued (Net)	31.19M	306.65M	371.85M	81M	18.16M	8.2M	25.13M	6.84M	49.88M
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0	0
Other Financing	0	0	0	0	0	0	0	0	0
Net Change in Cash	-94.2M▲ 0%	67.69M▲ 171.9%	54.88M▼ 18.9%	137.33M▲ 150.2%	-178.59M▼ 230.0%	-32.59M▲ 81.8%	73.81M▲ 326.5%	133.93M▲ 81.5%	-141.89M▼ 205.9%
Free Cash Flow	-218.67M▲ 0%	-169.62M▲ 22.4%	-152.26M▲ 10.2%	-143.75M▲ 5.6%	-126.78M▲ 11.8%	-114.03M▲ 10.1%	-23.35M▲ 79.5%	157.2M▲ 773.3%	105.15M▼ 33.1%
FCF Margin %	-175.07%	-75.79%	-44.9%	-32.54%	-26.19%	-22.05%	-3.21%	16.41%	9.81%
FCF Growth %	0.57%	22.43%	10.23%	5.59%	11.81%	10.05%	79.53%	773.27%	-33.11%
FCF per Share	-1.78	-1.34	-1.03	-0.91	-0.79	-0.71	-0.14	0.94	0.61
FCF Conversion (FCF/Net Income)	0.75x	0.68x	0.64x	0.48x	0.75x	0.53x	-0.27x	0.70x	0.28x
Interest Paid	0	0	0	0	0	0	0	0	0
Taxes Paid	1.37M	1.26M	1.6M	1.11M	1.04M	2.19M	5.85M	19.52M	0

ACAD Key Ratios

ACADIA Pharmaceuticals Inc. (ACAD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-75.58%	-67.8%	-60.22%	-39.93%	-42.47%	-28.75%	-45.89%	-14.73%	38.89%	39.89%
Return on Invested Capital (ROIC)	-90.45%	-70.67%	-60.83%	-42.82%	-49.42%	-31.62%	-41.64%	-16.99%	45.22%	10.03%
Gross Margin	74.58%	89.54%	91.81%	94.22%	95.35%	96.05%	98.03%	93.7%	91.46%	91.69%
Net Margin	-1565.94%	-231.71%	-109.56%	-69.38%	-63.74%	-34.67%	-41.76%	-8.44%	23.64%	36.49%
Debt / Equity	-	-	-	0.01x	0.08x	0.12x	0.15x	0.13x	0.07x	0.04x
FCF Conversion	0.78x	0.75x	0.68x	0.64x	0.48x	0.75x	0.53x	-0.27x	0.70x	0.28x
Revenue Growth	28311.48%	620.68%	79.19%	51.5%	30.28%	9.6%	6.83%	40.45%	31.85%	11.87%

ACAD SEC Filings & Documents

ACADIA Pharmaceuticals Inc. (ACAD) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 6, 2026·SEC

Material company update

Mar 5, 2026·SEC

Material company update

Feb 25, 2026·SEC

10-K Annual Reports

FY 2025

Feb 27, 2025·SEC

FY 2024

Feb 28, 2024·SEC

10-Q Quarterly Reports

FY 2025

Nov 6, 2025·SEC

FY 2025

Aug 7, 2025·SEC

FY 2025

May 8, 2025·SEC

ACAD Frequently Asked Questions

ACADIA Pharmaceuticals Inc. (ACAD) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

ACADIA Pharmaceuticals Inc. (ACAD) reported $1.07B in revenue for fiscal year 2025. This represents a 24749% increase from $4.3M in 2000.

ACADIA Pharmaceuticals Inc. (ACAD) grew revenue by 11.9% over the past year. This is steady growth.

Yes, ACADIA Pharmaceuticals Inc. (ACAD) is profitable, generating $391.0M in net income for fiscal year 2025 (36.5% net margin).

Dividend & Returns

ACADIA Pharmaceuticals Inc. (ACAD) has a return on equity (ROE) of 39.9%. This is excellent, indicating efficient use of shareholder capital.

ACADIA Pharmaceuticals Inc. (ACAD) generated $105.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More ACAD

ACADIA Pharmaceuticals Inc. (ACAD) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

ACADIA Pharmaceuticals Inc.(ACAD)Earnings, Financials & Key Ratios

ACAD Key Insights

✓Strengths

✗Weaknesses

ACAD Price & Volume

ACAD Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

ACAD Recent Earnings

ACAD Peer Comparison

Compare ACAD vs Peers

vs INVA

vs CVS

Compare Top 5

ACAD Income Statement

ACAD Balance Sheet

ACAD Cash Flow Statement

ACAD Key Ratios

ACAD SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

ACAD Frequently Asked Questions

Explore More ACAD

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation